Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

A double-blind, randomized, controlled, multi-center safety and immunogenicity study of a refrigerator-stable formulation of VARIVAX®.

Reisinger KS, Richardson E, Malacaman EA, Levin MJ, Gardner JL, Wang W, Stek JE, Kuter B.

Vaccine. 2019 Sep 10;37(38):5788-5795. doi: 10.1016/j.vaccine.2018.01.089. Epub 2018 Aug 23.

PMID:
30146405
2.

M-M-R(®)II manufactured using recombinant human albumin (rHA) and M-M-R(®)II manufactured using human serum albumin (HSA) exhibit similar safety and immunogenicity profiles when administered as a 2-dose regimen to healthy children.

Wiedmann RT, Reisinger KS, Hartzel J, Malacaman E, Senders SD, Giacoletti KE, Shaw E, Kuter BJ, Schödel F, Musey LK.

Vaccine. 2015 Apr 27;33(18):2132-40. doi: 10.1016/j.vaccine.2015.03.017. Epub 2015 Mar 18.

PMID:
25796337
4.

Analysis of safety data in children after receiving two doses of ProQuad® (MMRV).

Klopfer SO, Stek JE, Petrecz M, Reisinger KS, Black SB, Goveia MG, Nicholson O, Gardner JL, Grosso AD, Brown ML, Kuter BJ, Schödel FP.

Vaccine. 2014 Dec 12;32(52):7154-60. doi: 10.1016/j.vaccine.2014.08.067. Epub 2014 Sep 16.

PMID:
25219563
5.

Long-term study of a quadrivalent human papillomavirus vaccine.

Ferris D, Samakoses R, Block SL, Lazcano-Ponce E, Restrepo JA, Reisinger KS, Mehlsen J, Chatterjee A, Iversen OE, Sings HL, Shou Q, Sausser TA, Saah A.

Pediatrics. 2014 Sep;134(3):e657-65. doi: 10.1542/peds.2013-4144. Epub 2014 Aug 18.

PMID:
25136050
6.

Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: a phase III randomized controlled trial in children.

Langley JM, Carmona Martinez A, Chatterjee A, Halperin SA, McNeil S, Reisinger KS, Aggarwal N, Huang LM, Peng CT, Garcia-Sicilia J, Salamanca de la Cueva I, Cabañas F, Treviño-Garza C, Rodríguez-Weber MA, de la O M, Chandrasekaran V, Dewé W, Liu A, Innis BL, Jain VK.

J Infect Dis. 2013 Aug 15;208(4):544-53. doi: 10.1093/infdis/jit263. Epub 2013 Jul 11. Erratum in: J Infect Dis. 2014 May 1;209(9):1494.

7.

Safety and immunogenicity of a modified process hepatitis B vaccine in healthy neonates.

Minervini G, McCarson BJ, Reisinger KS, Martin JC, Stek JE, Atkins BM, Nadig KB, Liska V, Schödel FP, Bhuyan PK.

Vaccine. 2012 Feb 14;30(8):1476-80. doi: 10.1016/j.vaccine.2011.12.095. Epub 2012 Jan 5.

PMID:
22227229
8.

Safety and immunogenicity of a novel quadrivalent meningococcal CRM-conjugate vaccine given concomitantly with routine vaccinations in infants.

Klein NP, Reisinger KS, Johnston W, Odrljin T, Gill CJ, Bedell L, Dull P.

Pediatr Infect Dis J. 2012 Jan;31(1):64-71. doi: 10.1097/INF.0b013e31823dce5c. Erratum in: Pediatr Infect Dis J. 2012 Oct;31(10):1105.

PMID:
22094635
9.

Safety and tolerability of zoster vaccine in adults ≥60 years old.

Murray AV, Reisinger KS, Kerzner B, Stek JE, Sausser TA, Xu J, Wang WW, Chan IS, Annunziato PW, Parrino J.

Hum Vaccin. 2011 Nov;7(11):1130-6. doi: 10.4161/hv.7.11.17982. Epub 2011 Nov 1.

10.

Lactose-free milk protein-based infant formula: impact on growth and gastrointestinal tolerance in infants.

Lasekan JB, Jacobs J, Reisinger KS, Montalto MB, Frantz MP, Blatter MM.

Clin Pediatr (Phila). 2011 Apr;50(4):330-7. doi: 10.1177/0009922810390511.

PMID:
21436148
11.

Safety, tolerability, and immunogenicity of gardasil given concomitantly with Menactra and Adacel.

Reisinger KS, Block SL, Collins-Ogle M, Marchant C, Catlett M, Radley D, Sings HL, Haupt RM, Garner EI; Protocol 025 Investigators.

Pediatrics. 2010 Jun;125(6):1142-51. doi: 10.1542/peds.2009-2336. Epub 2010 May 3.

PMID:
20439595
12.

Optimizing protection against meningococcal disease.

Reisinger KS, Black S, Stoddard JJ.

Clin Pediatr (Phila). 2010 Jun;49(6):586-97. doi: 10.1177/0009922809354327. Epub 2010 Jan 20. Review.

PMID:
20089551
13.

Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) l1 virus-like particle vaccine.

Block SL, Brown DR, Chatterjee A, Gold MA, Sings HL, Meibohm A, Dana A, Haupt RM, Barr E, Tamms GM, Zhou H, Reisinger KS.

Pediatr Infect Dis J. 2010 Feb;29(2):95-101. doi: 10.1097/INF.0b013e3181b77906.

PMID:
19952863
14.

Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra.

Reisinger KS, Baxter R, Block SL, Shah J, Bedell L, Dull PM.

Clin Vaccine Immunol. 2009 Dec;16(12):1810-5. doi: 10.1128/CVI.00207-09. Epub 2009 Oct 7.

15.

Subunit influenza vaccines produced from cell culture or in embryonated chicken eggs: comparison of safety, reactogenicity, and immunogenicity.

Reisinger KS, Block SL, Izu A, Groth N, Holmes SJ.

J Infect Dis. 2009 Sep 15;200(6):849-57. doi: 10.1086/605506.

PMID:
19673652
16.

A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents.

Jackson LA, Jacobson RM, Reisinger KS, Anemona A, Danzig LE, Dull PM.

Pediatr Infect Dis J. 2009 Feb;28(2):86-91. doi: 10.1097/INF.0b013e31818a0237.

PMID:
19116603
17.

Characteristics of an ideal rotavirus vaccine.

Reisinger KS, Block SL.

Clin Pediatr (Phila). 2008 Jul;47(6):555-63. doi: 10.1177/0009922808314903. Epub 2008 May 8.

PMID:
18467670
18.

Comparative immunogenicities of frozen and refrigerated formulations of live attenuated influenza vaccine in healthy subjects.

Block SL, Reisinger KS, Hultquist M, Walker RE; CAIV-T Study Group.

Antimicrob Agents Chemother. 2007 Nov;51(11):4001-8. Epub 2007 Aug 27.

19.

Comparison of the safety and immunogenicity of a refrigerator-stable versus a frozen formulation of ProQuad (measles, mumps, rubella, and varicella virus vaccine live).

Bernstein HH, Eves K, Campbell K, Black SB, Twiggs JD, Reisinger KS, Conti RM, Flodmark CE, Rombo L, Klopfer S, Schödel F, Hartzel J, Kuter BJ; Refrigerator-Stable Formulation Study Group for ProQuad.

Pediatrics. 2007 Jun;119(6):e1299-305. Epub 2007 May 14.

PMID:
17502347
20.

Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial.

Reisinger KS, Block SL, Lazcano-Ponce E, Samakoses R, Esser MT, Erick J, Puchalski D, Giacoletti KE, Sings HL, Lukac S, Alvarez FB, Barr E.

Pediatr Infect Dis J. 2007 Mar;26(3):201-9.

PMID:
17484215
21.

Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women.

Block SL, Nolan T, Sattler C, Barr E, Giacoletti KE, Marchant CD, Castellsagué X, Rusche SA, Lukac S, Bryan JT, Cavanaugh PF Jr, Reisinger KS; Protocol 016 Study Group.

Pediatrics. 2006 Nov;118(5):2135-45.

PMID:
17079588
22.

Safety and immunogenicity of a combination measles, mumps, rubella and varicella vaccine (ProQuad).

Kuter BJ, Brown ML, Hartzel J, Williams WR, EvesiKaren A, Black S, Shinefield H, Reisinger KS, Marchant CD, Sullivan BJ, Thear M, Klopfer S, Xu J, Gress JO, Schödel F; Study Group for ProQuad.

Hum Vaccin. 2006 Sep-Oct;2(5):205-14.

PMID:
17035730
23.

A combination measles, mumps, rubella, and varicella vaccine (ProQuad) given to 4- to 6-year-old healthy children vaccinated previously with M-M-RII and Varivax.

Reisinger KS, Brown ML, Xu J, Sullivan BJ, Marshall GS, Nauert B, Matson DO, Silas PE, Schödel F, Gress JO, Kuter BJ; Protocol 014 Study Group for ProQuad.

Pediatrics. 2006 Feb;117(2):265-72. Erratum in: Pediatrics. 2006 Jun;117(6):2338.

PMID:
16452343
24.

A bovine parainfluenza virus type 3 vaccine is safe and immunogenic in early infancy.

Greenberg DP, Walker RE, Lee MS, Reisinger KS, Ward JI, Yogev R, Blatter MM, Yeh SH, Karron RA, Sangli C, Eubank L, Coelingh KL, Cordova JM, August MJ, Mehta HB, Chen W, Mendelman PM.

J Infect Dis. 2005 Apr 1;191(7):1116-22. Epub 2005 Feb 22.

PMID:
15747247
25.

Concomitant administration of a bivalent Haemophilus influenzae type b-hepatitis B vaccine, measles-mumps-rubella vaccine and varicella vaccine: safety, tolerability and immunogenicity.

Hesley TM, Reisinger KS, Sullivan BJ, Jensen EH, Stasiorowski S, Meechan C, Chan CY, West DJ; HIB-HB VACCINE STUDY GROUP.

Pediatr Infect Dis J. 2004 Mar;23(3):240-5.

PMID:
15014300
26.

Impact of a birth dose of hepatitis B vaccine on the reactogenicity and immunogenicity of diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b combination vaccination.

Pichichero ME, Blatter MM, Reisinger KS, Harrison CJ, Johnson CE, Steinhoff MC, Senders SD, Rothstein EP, Willems P, Howe BJ.

Pediatr Infect Dis J. 2002 Sep;21(9):854-9.

PMID:
12352809
27.

A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix-B) in adults.

Joines RW, Blatter M, Abraham B, Xie F, De Clercq N, Baine Y, Reisinger KS, Kuhnen A, Parenti DL.

Vaccine. 2001 Sep 14;19(32):4710-9.

PMID:
11535321
28.

Antibody responses to bovine parainfluenza virus type 3 (PIV3) vaccination and human PIV3 infection in young infants.

Lee MS, Greenberg DP, Yeh SH, Yogev R, Reisinger KS, Ward JI, Blatter MM, Cho I, Holmes SJ, Cordova JM, August MJ, Chen W, Mehta HB, Coelingh KL, Mendelman PM.

J Infect Dis. 2001 Oct 1;184(7):909-13. Epub 2001 Aug 15.

PMID:
11509996
29.

Oral oseltamivir treatment of influenza in children.

Whitley RJ, Hayden FG, Reisinger KS, Young N, Dutkowski R, Ipe D, Mills RG, Ward P.

Pediatr Infect Dis J. 2001 Feb;20(2):127-33. Erratum in: Pediatr Infect Dis J 2001 Apr;20(4):421.

PMID:
11224828
30.

An acellular pertussis vaccine in healthy adults: safety and immunogenicity. Pennridge Pediatric Associates.

Rothstein EP, Anderson EL, Decker MD, Poland GA, Reisinger KS, Blatter MM, Jacobson RM, Mink CA, Gennevois D, Izu AE, Sinangil F, Langenberg AG.

Vaccine. 1999 Aug 6;17(23-24):2999-3006.

PMID:
10462235
31.

Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants.

Rennels MB, Edwards KM, Keyserling HL, Reisinger KS, Hogerman DA, Madore DV, Chang I, Paradiso PR, Malinoski FJ, Kimura A.

Pediatrics. 1998 Apr;101(4 Pt 1):604-11.

PMID:
9521941
32.

Comparison of acellular pertussis-diphtheria-tetanus toxoids and Haemophilus influenzae type b vaccines administered separately vs. combined in younger vs. older toddlers.

Rennels MB, Hohenboken MJ, Reisinger KS, Clements DA, Walter EB Jr, Blatter MM, Nonenmacher J, Hackell JG.

Pediatr Infect Dis J. 1998 Feb;17(2):164-6. No abstract available.

PMID:
9493818
33.

Inactivated poliovirus vaccine alone or sequential inactivated and oral poliovirus vaccine in two-, four- and six-month-old infants with combination Haemophilus influenzae type b/hepatitis B vaccine.

Halsey NA, Blatter M, Bader G, Thoms ML, Willingham FF, O'Donovan JC, Pakula L, Berut F, Reisinger KS, Meschievitz C.

Pediatr Infect Dis J. 1997 Jul;16(7):675-9.

PMID:
9239772
34.

Reactogenicity and immunogenicity of a three-component acellular pertussis vaccine administered as the primary series to 2, 4 and 6 month old infants in the United States.

Bernstein HH, Rothstein EP, Pichichero ME, Green JL, Reisinger KS, Blatter MM, Halpern J, Arbeter AM, Bernstein DI, Smith V, et al.

Vaccine. 1995 Dec;13(17):1631-5.

PMID:
8719512
35.

Comparison of a three-component acellular pertussis vaccine with a whole-cell pertussis vaccine in 4- through 6-year-old children. Elmwood Pediatric Associates, Pennridge Pediatric Associates.

Annunziato PW, Rothstein EP, Bernstein HH, Blatter MM, Reisinger KS, Pichichero ME.

Arch Pediatr Adolesc Med. 1994 May;148(5):503-7.

PMID:
8180641
36.

Comparison of a three-component acellular pertussis vaccine with a whole-cell pertussis vaccine in 15- through 20-month-old infants.

Bernstein HH, Rothstein EP, Reisinger KS, Blatter MM, Arbeter AM, Fontana ME, Jacobs JM, Long SS, Rathfon H, Crayne O, et al.

Pediatrics. 1994 Apr;93(4):656-9.

PMID:
8134224
37.

Clinical survey of natural varicella compared with breakthrough varicella after immunization with live attenuated Oka/Merck varicella vaccine.

Bernstein HH, Rothstein EP, Watson BM, Reisinger KS, Blatter MM, Wellman CO, Chartrand SA, Cho I, Ngai A, White CJ.

Pediatrics. 1993 Dec;92(6):833-7.

PMID:
8233746
38.

Safety and immunogenicity of a combined diphtheria, tetanus, pertussis and Haemophilus influenzae type b vaccine in young infants.

Paradiso PR, Hogerman DA, Madore DV, Keyserling H, King J, Reisinger KS, Blatter MM, Rothstein E, Bernstein HH, Hackell J.

Pediatrics. 1993 Dec;92(6):827-32.

PMID:
8233745
39.

Immunogenicity of Haemophilus influenzae type b polysaccharide-tetanus toxoid conjugate vaccine in infants.

Holmes SJ, Fritzell B, Guito KP, Esbenshade JF, Blatter MM, Reisinger KS, Keyserling HL, Rothstein EP, Bernstein HH, Feldman S, et al.

Am J Dis Child. 1993 Aug;147(8):832-6.

PMID:
8352217
40.

Comparative study of sultamicillin and amoxicillin-clavulanate: treatment of acute otitis media.

Chan KH, Bluestone CD, Tan LS, Reisinger KS, Blatter MM, Fall PA.

Pediatr Infect Dis J. 1993 Jan;12(1):24-8.

PMID:
8417421
41.

Acellular pertussis vaccination of 2-month-old infants in the United States.

Pichichero ME, Francis AB, Blatter MM, Reisinger KS, Green JL, Marsocci SM, Disney FA.

Pediatrics. 1992 May;89(5 Pt 1):882-7.

PMID:
1579399
42.

Immunogenicity of subcutaneous versus intramuscular Oka/Merck varicella vaccination in healthy children.

Dennehy PH, Reisinger KS, Blatter MM, Veloudis BA.

Pediatrics. 1991 Sep;88(3):604-7.

PMID:
1881743
43.

Amoxicillin or myringotomy or both for acute otitis media: results of a randomized clinical trial.

Kaleida PH, Casselbrant ML, Rockette HE, Paradise JL, Bluestone CD, Blatter MM, Reisinger KS, Wald ER, Supance JS.

Pediatrics. 1991 Apr;87(4):466-74.

PMID:
2011422
44.

Comparison of an acellular pertussis-component diphtheria-tetanus-pertussis (DTP) vaccine with a whole-cell pertussis-component DTP vaccine in 17- to 24-month-old children, with measurement of 69-kilodalton outer membrane protein antibody.

Blumberg DA, Mink CM, Cherry JD, Reisinger KS, Blatter MM, Congeni BL, Dekker CL, Stout MG, Mezzatesta JR, Scott JV, et al.

J Pediatr. 1990 Jul;117(1 Pt 1):46-51.

PMID:
2196360
45.

Comparison of acellular and whole-cell pertussis-component DTP vaccines. A multicenter double-blind study in 4- to 6-year-old children.

Morgan CM, Blumberg DA, Cherry JD, Reisinger KS, Blatter MM, Blumer JL, Dekker CL, Stout MG, Christenson PD.

Am J Dis Child. 1990 Jan;144(1):41-5.

PMID:
2403747
46.

A comparative study of amoxicillin-clavulanate and amoxicillin. Treatment of otitis media with effusion.

Chan KH, Mandel EM, Rockette HE, Bluestone CD, Bass LW, Blatter MM, Breck JM, Reisinger KS, Wolfson JH, Wucher FP, et al.

Arch Otolaryngol Head Neck Surg. 1988 Feb;114(2):142-6.

PMID:
3276343
47.

Cefixime vs. cefaclor in the treatment of acute otitis media in infants and children.

Kenna MA, Bluestone CD, Fall P, Stephenson J, Kurs-Lasky M, Wucher FP, Blatter MM, Reisinger KS.

Pediatr Infect Dis J. 1987 Oct;6(10):992-6. No abstract available.

PMID:
3696840
48.

Sultamicillin (ampicillin-sulbactam) in the treatment of acute otitis media in children.

Kaleida PH, Bluestone CD, Blatter MM, Reisinger KS, Wucher FP, Fall PA, Rohn DD.

Pediatr Infect Dis. 1986 Jan-Feb;5(1):33-8.

PMID:
3003716
49.

Comparison of bacampicillin and amoxicillin in acute otitis media with effusion.

Kim HK, Bluestone CD, Blatter MM, Reisinger KS, Wucher FP, Rohn DD, Fall P, Digaudio K, Rebholz L.

Bull N Y Acad Med. 1983 Jun;59(5):515-23. No abstract available.

50.

Quantitative cultures of middle-ear fluid in acute otitis media.

Wald ER, Rohn DD, Chiponis DM, Blatter MM, Reisinger KS, Wucher FP.

J Pediatr. 1983 Feb;102(2):259-61. No abstract available.

PMID:
6822934

Supplemental Content

Loading ...
Support Center